NEW YORK (GenomeWeb) – Vela Diagnostics said that the China Food and Drug Administration has approved its Sentosa SX Cell-free DNA Kit.
The kit is designed to extract cell-free circulating DNA from plasma and is developed for use in real-time PCR and next-generation sequencing workflows. It runs on Vela's Sentosa SX101 instrument, an automated liquid handling system for DNA extraction.
The extraction kit efficiently recovers cfDNA fragments, including low-frequency variants down to 5 percent allele frequency, and requires 20 minutes of operator hands-on time, according to the company.
"We are excited to have obtained approval of this kit in the liquid biopsy space, and we are looking forward to further collaborations in oncology," Vela Biosciences' General Manager in Shanghai, Ryan Tay, said in statement.